The naive phenotype of cord blood (CB) T-cells may reduce graft versus host disease after umbilical cord blood transplant (CBT), but this naivety and their low absolute numbers also delays immune reconstitution, producing higher infection-related mortality that is predominantly related to CMV, adenovirus (Adv) and EBV. Adoptive immunotherapy with peripheral blood-derived virus-specific cytotoxic T-lymphocytes 
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for selected patients with high-risk hematologic malignancies. However a significant proportion of patients -especially non-Caucasians -lack a marrow or peripheral blood stem cell donor. Umbilical cord blood (CB) has therefore emerged as an important alternative source of stem cells for allotransplant patients. 1;2 The major advantages of CB transplants (CBT) compared to unrelated adult donor stem cells include more rapid procurement of the graft, the requirement for less stringent HLA matching, the higher likelihood of finding a match for ethnic minorities, and a decreased incidence of graft versus host disease (GVHD). Although a major disadvantage of CB is the low cell stem cell dose, which results in delayed engraftment, there is also delayed immune recovery, particularly in mismatched unrelated cord blood transplants utilizing anti-thymocyte globulin (ATG). 3 This is attributed to the small numbers of T-cells transferred, the absence of memory T-cells within the CB grafts and the apparent hyporesponsiveness of CB antigen presenting cells. Consequently, CB recipients are susceptible to an array of viral and other infections that are the leading cause of death in these patients. [3] [4] [5] [6] [7] Cytomegalovirus (CMV), Epstein Barr Virus (EBV) and Adenovirus (Adv) are particularly problematic in the immunocompromised recipient, and are associated with significant morbidity and mortality. [8] [9] [10] Although anti-viral drugs can be beneficial for CMV and EBV, effective agents are unavailable for adenovirus, all have substantial toxicities and drug resistance may occur. These deficiencies in conventional therapeutics have increased interest in an immunotherapeutic approach to viral disorders, and adoptive transfer of For personal use only. on December 30, 2017 . by guest www.bloodjournal.org From monoculture-derived multi-virus specific CTL from CMV-seropositive donors can prevent and treat CMV, EBV and Adenoviral disease post-HSCT without significant toxicities. 11 There are significant conceptual obstacles to extending this approach to the recipients of CB transplants. Only limited numbers of CB T-cells are available for manipulation, and these cells have a naïve phenotype, making them incapable of conferring protection against CMV, EBV and Adv during engraftment. 3;12 Hence, the development of virusprotective T-cell therapy for CBT recipients requires the priming and extensive expansion of naïve T-cells rather than the more limited and simple direct expansion of a pre-existing virus specific memory T-cell population. This task is made even more challenging since CB T-cells have lower cytotoxic activity and higher activation-induced cell death than peripheral blood-derived T-cells. 13;14 These limitations have prevented the successful generation of virus-specific cord blood-derived CTL in sufficient numbers for clinical use as prophylactic therapy of CMV, EBV and adenoviral infections after CBT.
It has become evident that in addition to antigen presentation and intercellular costimulation, the ex vivo priming of antigen-specific T-cells requires the presence of appropriate soluble cytokines. Hence, IL-7, IL-15, and IL-12 respectively decrease the antigen concentration threshold, direct T-cells towards a central memory phenotype, and influence the polarization of Th1 cells. In combination these cytokines augment the generation of antigen specific CTL from naïve T-cells. 15 We now describe how Ad5f35pp65-transduced CB-derived antigen presenting cells can be used to generate large numbers of T-cells that are specific for both CMV and
Adenovirus even from the naive T-cell population in human CB. Incorporation of EBVtransformed B-lymphoblastoid cell lines in the antigen presenting cells further allows the Adv/CMV specificity of the CB T-cells to be extended to EBV. The cells we describe have broad epitope specificity, and are cytolytic to CMV, Adv and EBV target cells.
Hence they may be protective in vivo.
MATERIALS AND METHODS

Cord Blood Units
Virus-specific CTL were generated from CB units obtained frozen from the MDACC Cord Blood bank or fresh from mothers who had consented to the protocol approved by the IRB of Baylor College of Medicine. To ensure the future clinical feasibility of this approach, we also froze the fresh CB units in DMSO containing 50% human serum prior to use for the generation of CB-derived CTL, thereby mimicking the likely clinical setting.
All cord bloods were typed by the HLA laboratory of The Methodist Hospital, and we used CB from donors with multiple HLA types ( Table 1) . To further ensure that the approach would be feasible clinically, a total of only forty million CB mononuclear cells (which can be obtained from the 20% fraction of frozen CB units) were thawed and used in the manufacturing process. According to our IRB approval clinical protocol patients must have a single CB unit matched with the patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens. The unit must be cryopreserved in two fractions, with a minimum of 2.5x10 7 total nucleated cells per kg pre-thaw in the fraction which will be used for the primary transplant. The remaining fraction will be used to generate the CTLs to give at day 30 or beyond as described below. This cell dose has been found to support acceptable engraftment in both pediatric and adult patients and is a commonly used minimal cell dose target in the cord blood transplant community. 16 For personal use only. on December 30, 2017 . by guest www.bloodjournal.org From
Generation of Dendritic Cells (DC) from Cord Blood
Umbilical cord blood was thawed and then purified by Ficoll (Lymphoprep; Nycomed, Oslo, Norway) gradient separation. 30 x10 6 CBMC were washed twice and resuspended in CellGenix media (CellGenix USA, Antioch, IL) and plated at 5x10 6 cells per well in DC medium (CellGenix media plus 2 mM L-glutamine) (GlutaMAX, Invitrogen, Carlsbad, CA) in a 6-well plate (Costar, Corning, NY) for 2 hr at 37°C in a humidified CO 2 incubator.
Non-adherent cells were removed by rinsing with 1X PBS (GibcoBRL, Gaithersburg, Maryland), and refrozen. Loosely adherent cells were cultured in DC media with 800 U/ml GM-CSF (Sargramostim Leukine; Immunex, Seattle, WA) and 500 U/ml IL-4 (R&D Systems, Minneapolis, MN, USA) for 7 days. IL-4 and GM-CSF were again added on day 3. On day 5, cells were harvested for transduction. 
Transduction of Dendritic cells
Generation of Multivirus-specific Cultures Derived from Umbilical Cord Blood
Frozen CBMC were thawed, washed and resuspended in 45% RPMI (Hyclone) and 45%
CLICKS (Irvine Scientific) with 10% Human Serum plus GlutaMAX TM -I (CTL medium).
Cells were resuspended at 2x10 6 /ml and co-cultured with autologous, irradiated transduced DCs at a ratio of 20 CBMC to 1 DC in the presence of the cytokines IL-7, IL-12, (R&D Systems) and IL-15 (CellGenix), all at 10ng/mL. Cultures were restimulated on day 10 with irradiated Ad5f35CMVpp65-transduced LCL at a responder-to-stimulator ratio of 4:1 plus IL-15 (10ng/ml), and 1 week later with irradiated autologous Ad5f35CMVpp65-transduced LCL at a responder-to-stimulator ratio of 4:1. IL-2 (50-100 U/ml, Proleukin; Chiron, Emeryville, CA) was added 3 days after the second stimulation and then twice weekly.
To define the origin of the virus-specific T-cell population we sorted CD45RA/CCR7 double positive (DP) and double negative (DN) CD3+ T-cell populations using flow cytometry and stimulated the DP and DN populations with transduced DC followed by transduced LCL as described above. Samples were acquired on a FACScan flow cytometer (Becton Dickinson) and the data analyzed using CellQuest software (Becton Dickinson).
Enzyme-Linked Immunospot (ELISPOT) assay
ELISPOT analysis was used to determine the frequency and function of T-cells secreting IFN-γ in response to pepmixes™ (Jerini, Berlin, Germany) for CMVpp65, AdvHexon, AdvPenton and CMVIE1 which contain all 15mer peptides of each viral antigen in one pool. 11 ELISPOT assays were performed on the CTL lines. In addition, to define the CD4 and CD8 restricted CMVpp65-specific activity we pulsed CD8+ or CD4+ T-cells (sorted from CTL lines using flow cytometry) with CMV peptides. 18 CBMC stimulated with CMVIE1 pepmix and Staphylococcal Enterotoxin B (1μg/ml) (Sigma-Aldrich Corporation, St Louis, MO) served as controls. Spot-forming cells (SFC) were enumerated by Zellnet Consulting (New York, New York) and compared with input cell numbers to obtain the frequency of virus reactive T-cells.
Multimers and peptides
To detect CMVpp65-specific T-cells in the CTL lines, we used the soluble HLA-peptide is previously described. 19 For each sample, 100,000 cells were analyzed as described above.
Panels of 20mer peptides (overlapping by 15 amino acids) covering the entire amino acid sequence of CMVpp65 from the AD169 strain and adenovirus hexon from serotype 5 were synthesized. 18;20 For CMVpp65, twenty-two peptide pools comprising 2 to twelve 15mer peptides were prepared, so that each 20mer peptide was represented in two pools. 20 For Advhexon, eleven peptide pools contained 17 or 18 peptides, so that each 20mer peptide was represented in one pool, and we then screened the positive pools as previously described. 18 These CMVpp65 and Advhexon peptide libraries were designed to identify all possible HLA class I restricted epitopes, which have a length of 9-11 amino acids, and to also identify HLA class II restricted epitopes, which have lengths of 13 to 17 amino acids.
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Cytotoxicity assay
CTLs were tested for specific cytotoxicity against autologous LCL 22 , PHA blasts pulsed with CMVpp65 pepmix (Jerini) or adenovirus hexon pepmix. As control target cells we used unpulsed PHA blasts, PHA blasts pulsed with irrelevant peptides and HLA class Imismatched LCLs. 51 Cr-labeled target cells were mixed with effector cells at doubling dilutions to produce the effector: target (E: T) ratios specified. Target cells incubated in complete medium or 5% Triton X-100 (Sigma) were used to determine spontaneous and maximal 51 Cr release, respectively. After 4 hours (LCLs and PHA blasts) or 6 hours (fibroblasts), supernatants were collected and radioactivity was measured on a gamma counter. The mean percentage of specific lysis of triplicate wells was calculated as 100 × (experimental release -spontaneous release)/(maximal release -spontaneous release).
Statistical analysis
The Student t test was used to test for significance in each set of values, assuming equal variance. Mean values ± SD are given unless otherwise stated.
RESULTS
Expanded Cord Blood-derived CTLs are Virus-specific and Polyclonal
We prepared T-cell lines from 9 different cord blood units. After growth on We next used cytotoxicity and IFNγ ELISPOT assays to discover if the T-cell lines were indeed trivirus specific cytotoxic T lymphocytes (CTLs). Cytotoxic activity was tested against a panel of 51 Cr-labeled autologous and allogeneic target cells and showed that the CTL lines killed PHA blasts only if they were pulsed with CMVpp65 pepmix or Advhexon pepmix (40% and 13% respectively at an E: T ratio of 20:1 (Figure 1c) ).
Furthermore, autologous EBV-LCLs were also killed in this assay, showing an EBVspecific T-cell component. There was no cytotoxic activity against unpulsed PHA blasts, PHA blasts pulsed with CMVIE1 pepmix (Figure 1c) or against HLA-mismatched EBVLCLs (data not shown).
Similarly, Figure 1d illustrates that after three stimulations, virus-specific T-cell lines 
Virus-specific CTL are expanded from the naïve CCR7/CD45RA+ T-cell population
We derived the virus specific CTLs described above from cord blood, which should lack an EBV, CMV or Adv specific memory T-cell compartment. To determine whether the virus-specific T-cells were indeed expanded from T-cells with a naïve phenotype (i.e.
CCR7+/CD45RA+ T-cell populations 23 ), the mononuclear cells from 3 cord units (two from CMV seronegative mothers and one from a CMV seropositive mother) were incubated with antibodies for CD45RA and CCR7. We used flow cytometry to sort Tcells that were either double positive for both CD45RA and CCR7 or double negative for CD45RA and CCR7 (Figure 2a) . Each of these populations was stimulated with transduced autologous antigen presenting cells and the virus specific activity evaluated using IFNγ ELISPOT. After three stimulations, the phenotypes of the resultant CTL lines The results from Adv hexon peptide pool screening of 6 evaluable CTL lines are summarized in Table 2 . Of the six CTL lines, three had reactivity against one adenovirus hexon epitope and two lines had reactivity against multiple hexon epitopes. Three lines had reactivity against adenovirus penton. The hexon epitopes identified in these cord blood CTL lines were the same CD4-restricted epitopes as those identified in the multivirus CTL lines generated from adult peripheral blood.
18 Figure 3 shows the details of such analyses from two of these cord blood derived CTL lines. One line reacts predominantly against pool 1 (Figure 3a) and the other against pool 10 (Figure 3b ). Subsequent analysis with individual 20mer peptides contained in these pools shows that the CTL reactivity in pool 1 could be mapped to overlapping (Figure 3c) , while CTL reactivity directed against pool 10 could be mapped to overlapping peptide 6 (aa 791-814 MYSFFRNFQPMSRQVVDDTK) and peptide 7 (aa 796-815 RNFQPMSRQVVDDTKYKDYQ) (Figure 3d) . Thus cord blood derived CTLs have a similar pattern of epitope recognition to adult blood derived CTLs. Furthermore, these epitopes are CD4-restricted with apparent immunodominance since they have previously detected in multiple CTL lines derived from peripheral blood.
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Virus-specific CTL derived from Cord Blood Recognizes unconventional CD4 and
CD8 restricted CMVpp65 epitopes
We characterized the CMVpp65 epitope specificity of the CTLs by incubating them with CMVpp65 peptide pools 20 and measuring IFNγ release by ELISPOT assays. Table 3 illustrates that evaluable virus-specific lines derived from umbilical cord blood can Table 3) . These results are in contrast to CTL lines generated from peripheral blood donors 11 with these HLA types where 11/11 CTL lines exhibited specific activity against these immunodominant epitopes ( Table 4) .
To characterize the EBV-specific T-cell response, we screened the CTL lines for known immunodominant epitopes in EBNA 3, BZLF1 and LMP2. 25 We found, however, no evidence for such dominant-epitope specific T-cells (data not shown).
Virus-specific CTL derived from Cord Blood are expanded from Neonatal and not
Maternal T-cells
To confirm that the virus-specific T-cell responses observed in the cord blood derived CTL lines were of neonatal and not maternal origin we used fluorescence in situ hybridization (FISH) with sex chromosome-specific probes. X and Y chromosomes were identified by red and green fluorescence, respectively ( Figure 5 ). Of the 200 metaphases analyzed, 199 were positive for X and Y confirming that the cells were of cord blood origin. For an additional three CTL lines from female neonates, the HLA types of the mother were known. As shown in Table 1 the maternal HLA types were compared to the CTL lines generated from cords C1000.4, C1001.4 and C1002.4. In all three, only a single maternal HLA haplotype was found, so that the CTL line was derived from neonatal not maternal T-cells.
For
DISCUSSION
This study provides the first direct evidence that antigen-specific T-cells targeting multiple viral epitopes from Adv, CMV and EBV can be primed simultaneously from CB T-cells with a naïve phenotype. In addition, the multi-virus specific T-cells recognize an array of epitopes after only 2 weeks expansion in vivo. Notably, the pattern of CMV epitopes recognized appears to be different to "adult"-derived virus specific T-cells, while the recognition of Adv epitopes is the same.
Park et al 26 have previously shown that CMV-specific T-cells can be generated in vitro from umbilical cord blood, but the antigen and epitope specificity of the CMV-specific CTL was largely uncharacterized. Moreover, it was unclear whether the CMV-specific CTL they detected were derived from T-cells with a naïve CD45RA+/CCR7+ phenotype 27 . Questions also remained as to whether their CB-derived CTL came from contaminating maternal blood cells. Our current study addresses these limitations and also establishes the technology for simultaneously generating CTLs that are specific for all three of the commonest viral infections after CBT, using a clinically relevant and GMP compliant methodology.
Cord blood-derived T-cells can respond to endogenous antigens such as minor histocompatibility antigens that are disparate between mother and fetus, and to exogenous antigens such as parasites and environmental allergens. In our study, however, it was evident that the For personal use only. on December 30, 2017 . by guest www.bloodjournal.org From responses we obtained were derived by in vitro priming of the naive population of Tcells, and could be obtained irrespective of whether the mother was CMV seropositive or consistently seronegative, pre and post term. We showed that these cells were not of maternal origin and moreover, placental tissue from our donors was Adenovirus and CMV negative by PCR analysis and by immunohistochemistry, further excluding the possibility of priming in utero (data not shown). 12 Although our ex vivo expanded cord blood derived multi-virus specific T-cells developed a memory phenotype profile that was similar to peripheral blood derived multi-virus specific T-cells 11 , their epitope specificity could be strikingly different. Thus, none of the CB-derived CTL lines recognized the strongly immunodominant epitopes that are universally identified in the peripheral blood CMVpp65 CTL lines generated from CMVseropositive donors (Table 4) , with a preference instead for unconventional and even novel CMVpp65 epitopes. Cord blood T-cells may be a transitional population between thymocytes and adult T-cells 28 , so that the specificities we describe may thus represent a "default response" by recent thymic emigrants, which have not undergone post natal selection for more specific, and perhaps higher affinity anti-viral reactivity. 22;32 This hypothesis is supported by the broad Vβ repertoire we observed in cord blood-derived CTL using spectratyping (data not shown). Murine studies revealing that promiscuous low affinity TCR/MHC-peptide interactions on the surface of functionally immature neonatal T-cells leads to an intensive "burst" of short-lived cellular immunity prior to the establishment of conventional T-cell memory mediated by high affinity T-cells. 33 Our own human in vitro and the murine in vivo studies appear to reflect physiological events in humans, since CMV infected fetuses are also deficient in CD8+ T-cells responding to the canonical, immunodominant, B7-restricted RPH and A2-restricted NLV epitopes. 31 For personal use only. on December 30, 2017 . by guest www.bloodjournal.org From Notwithstanding the recognition of non-canonical epitopes, cord blood-derived CMVspecific CTL are capable of specifically lysing CMVpp65-pulsed targets. Moreover, these usually "subdominant" CMV epitopes still successfully compete against Adv hexon epitopes, since CTLs responding to CMV-pp65 continue to exceed in number the CTLs responding to Adv hexon, a characteristic they share with memory-cell derived CTLs directed to canonical pp65 epitopes.
While the specificity of cord blood naïve T-cell responses to CMV were markedly different from adult seropositive peripheral blood T-cells, the responses of the two T-cell populations to Adv virus were, perhaps surprisingly, indistinguishable. Using pools of overlapping 20-mer peptides for hexon and pp65, we identified T-cells specific for the same immunodominant CD4-restricted hexon epitopes found in adult seropositive donors, such as the hexon peptides that span amino acids 791-815 (MYSFFRNFQPMSRQVVDDTKYKDYQ). 18 We do not know why cord and peripheral blood T-cells should share epitope recognition for Adv but not CMV, but the difference likely reflects the profoundly different biology of the two viruses. Adenovirus is an acute infection that elicits strong innate immunity, followed by an adaptive CD4-restricted hexon-specific T-cell response that in turn maximizes the range of epitopes recognized by CD4+ and CD8+ effector cells. 18 As a latent virus, however, CMV recruits a dominant and oligoclonal CD8+ response. 34 Cord blood T-cells are biased towards a Th2 phenotype, 28 which may support development of a conventional adenoviral CD4-specific T-cell response, but which in combination with the immaturity of the responding cord blood T-cells, may redirect the CMV response away from the canonical epitopes.
Our explanation leads us to predict that our cord blood T-cell responses to EBV, a latent virus like CMV, would also be to non-dominant epitopes. An evaluation for non-canonical (Figures 1c and 1d) These observations are at least consistent with the differences we propose between cord blood naive T-cell responses to acute and latent viral antigens.
Although we were able to generate multi-virus specific CTL from cord blood, success was only achieved when we supplemented the cultures with IL-7, IL-12, and IL-15. Such supplementation is unnecessary for the generation of virus specific CTLs from adult memory T-cells, 11 and may simply indicate a lack of memory T-cell precursors and/or a deficiency of cord blood APC secretion of these cytokines. Neonatal dendritic cells certainly appear to have a deficiency in IL-12 production, and we have shown how cytokine supplementation can overcome these limitations. 35 In the current studies, it is possible that the altered epitope recognition we observed in the CMV responses are a consequence of the addition of these supplementary cytokines. This seems unlikely as the sole explanation for the phenomenon not only in view of the supporting data from murine and human studies described above, but also because the responses to Adv hexon epitopes were unchanged. Hence, we believe these differences more likely reflect intrinsic differences in the responsiveness of naive CB versus memory T-cells derived from CMV seropositive donors.
While antiviral pharmacotherapy may help prevent or treat CMV 36;37 and CD20 specific antibodies may control EBV-associated lymphoproliferation, 38 these drugs are expensive, toxic and often ineffective due to primary or secondary resistance 39 .
allogeneic HSCT and CBT and effective treatments are not currently available. 37 Strategies to reduce the incidence of viral infections after CBT include using grafts with the best HLA match and higher TNC, changes in conditioning and GvHD prophylaxis regimens. However, adoptive transfer of peripheral blood derived T-cell lines enriched in cells recognizing CMV, EBV and Adv can reproducibly control infections due to all three viruses after allogeneic HSCT 11 in a cost-effective manner. We suggest that our ability to generate virus-specific CTL from cord blood against a plethora of epitopes recognized by both CD4+ and CD8+ T-cells should minimize the risk of viral escape and maximize therapeutic benefit on administration of these cells to cord blood recipients at risk of severe viral disease. 
